Related Experiment Video
Updated: Jul 16, 2026

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry
Published on: November 21, 2012
Acute Methiopropamine Intoxication After "Synthacaine" Consumption.
A Daveluy1, N Castaing2, H Cherifi3
1Service de pharmacologie médicale, centre d'addictovigilance, CHU Bordeaux.
Methiopropamine (MPA), a synthetic stimulant, caused acute toxicity in a patient using "synthacaine." This case highlights the need for advanced toxicological analysis to identify new psychoactive substances.
Area of Science:
- Clinical Toxicology
- Pharmacology
- Forensic Science
Background:
- Methiopropamine (MPA), a synthetic amphetamine analog, has been increasingly detected in Europe since 2011.
- Limited data exists regarding the acute toxicity profile of MPA.
Observation:
- A 30-year-old male presented with acute confusion, paranoia, and hallucinations after consuming "synthacaine."
- Clinical examination revealed altered mental status and incoherent speech.
Findings:
- Toxicological analysis using LC-MS-MS confirmed the presence of MPA in the patient's plasma.
- MPA concentration was measured at 14 ng/mL, 13 hours post-admission.
Implications:
- This case confirms the acute toxicity of methiopropamine.
- Highlights the critical role of sophisticated toxicological screening in identifying novel psychoactive substances.
- Underscores the potential dangers associated with designer drugs like synthacaine.
Related Concept Videos
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Drugs Affecting Neurotransmitter Synthesis
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Toxidromes: Clinical Features

